Vitalist CRO Nick Padula departs post Somatix integration
Vitalist Inc. announced the departure of Chief Revenue Officer Nick Padula following the integration of Somatix Inc. Commercial and sales operations will now report directly to CEO Kalvie Legat, while health and wellness business development remains under Dr. Charles Herman.

*this image is generated using AI for illustrative purposes only.
Vitalist Inc. announced that Chief Revenue Officer Nick Padula will depart the company following his support of the post-acquisition integration and commercial transition of Somatix Inc. The leadership change marks the completion of the integration phase for the subsidiary acquired by Vitalist.
Nick Padula and the Vitalist team are collaborating to ensure a seamless hand-off of responsibilities over the coming weeks. The company expressed appreciation for Mr. Padula's leadership during his tenure, specifically regarding his efforts in guiding the integration and transition since the acquisition of Somatix Inc.
In connection with the departure, Vitalist is restructuring its reporting hierarchy. Commercial and sales operations will now report directly to CEO Kalvie Legat. Additionally, health and wellness business development will continue to report through Dr. Charles Herman, who serves as the Chief Scientific Officer (CSO) of Vitalist and CEO of Somatix Inc.
Organizational Structure
The following table outlines the updated reporting lines within Vitalist Inc.:
| Function | Reporting Executive | Title |
|---|---|---|
| Commercial and Sales Operations | Kalvie Legat | CEO |
| Health and Wellness Business Development | Dr. Charles Herman | CSO, Vitalist; CEO, Somatix Inc. |
Vitalist Inc. is a technology provider that enables brands to create connected devices and applications through its VitalOS platform. The company focuses on uniting hardware and software with intelligent analytics to build personalized solutions.
How will the direct reporting of commercial and sales operations to the CEO impact Vitalist's go-to-market strategy?
Does the departure of the CRO signal a shift in focus from post-acquisition integration to organic growth?
Who will Vitalist appoint to lead commercial strategy, and will they prioritize hardware or software solutions?

























